James Talarico, the Democratic nominee for U.S. Senate in Texas, released an ad accusing Elon Musk of trying to "buy" the Senate seat by heavily funding Republican Ken Paxton's campaign. Musk, the largest individual donor in the 2026 midterms with about $366 million spent across 40 races, has poured at least $189.6 million into Paxton's campaign. The feud escalated with mutual insults on social media as the midterm election approaches, with polls showing Talarico slightly ahead. This highlights concerns over the influence of wealthy donors in key political races.
The Texas Senate race involving James Talarico and Elon Musk provides context for market watchers. For readers following Consumer Cyclical-sector US stocks on Pluang, here is the market snapshot as of Oct 23, 2026 21:01 WIB: out of 134 priced stocks, 13 rose and 119 fell. Notable movers include GTX (Garrett Motion Inc. Common Stock) at USD 20.80 with a 1-day change of -5.45% and a typical hold time of 14 days, ATER (Aterian Inc) at USD 0.66 with a 1-day change of +5.36% and Pluang order activity of 56% Sell / 44% Buy, and NCLH (Norwegian Cruise Line Holdings Ltd) at USD 14.80 with a 1-day change of -4.76% and a typical hold time of 69 days.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
